A non-glycosylated, plant-produced human monoclonal antibody against anthrax protective antigen protects mice and non-human primates from B. anthracis spore challenge

Human Vaccines

Volumn 7, Issue SUPPL., 2011, Pages 183-190

  Mett, Vadim ^a   Chichester, Jessica A ^a   Stewart, Michelle L ^a   Musiychuk, Konstantin ^a   Bi, Hong ^a   Reifsnyder, Carolyn J ^a   Hull, Anna K ^a   Albrecht, Mark T ^b   Goldman, Stanley ^c   Baillie, Les W J ^d   Yusibov, Vidadi ^a  

^a Fraunhofer USA Inc   (United States)

^b NAVAL MEDICAL RESEARCH CENTER   (United States)

^c Genetic Chemistry Inc   (United States)

^d CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Glycosylation; Inhalation anthrax; Passive protection; Plant derived monoclonal antibody; Protective antigen

Indexed keywords

ANTHRAX TOXIN; HUMAN MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTHRAX; AREA UNDER THE CURVE; BACILLUS ANTHRACIS; BACTERIAL SPORE; BACTERIAL STRAIN; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; FEMALE; GLYCOSYLATION; IN VITRO STUDY; INFECTION PREVENTION; MALE; MOUSE; NICOTIANA BENTHAMIANA; NONHUMAN; PASSIVE IMMUNIZATION; PRIMATE; PROVOCATION TEST; REVIEW; SINGLE DRUG DOSE; SURVIVAL RATE; TREATMENT DURATION;

ANIMALS; ANTHRAX; ANTIBODIES, BACTERIAL; ANTIBODIES, MONOCLONAL; ANTIGENS, BACTERIAL; ANTITOXINS; BACTERIAL TOXINS; DISEASE MODELS, ANIMAL; MACACA FASCICULARIS; MALE; MICE; MICE, INBRED BALB C; PLANTS, GENETICALLY MODIFIED; PRIMATE DISEASES; RECOMBINANT PROTEINS; RODENT DISEASES; SURVIVAL ANALYSIS; TOBACCO; TREATMENT OUTCOME;

EID: 84855732241     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.7.0.14586     Document Type: Review

References (55)

1. Ross JM. The pathogenesis of anthrax following the administration of spores by the respiratory route. J Clin Pathol 1957; 73:485-94.
2. Collier RJ. Membrane translocation by anthrax toxin. Mol Aspects Med 2009; 30:413-22.
3. Moayeri M, Leppla SH. Cellular and systemic effects of anthrax lethal toxin and edema toxin. Mol Aspects Med 2009; 30:439-55.
4. Tang WJ, Guo Q. The adenylyl cyclase activity of anthrax edema factor. Mol Aspects Med 2009; 30:423-30.
5. Tonello F, Montecucco C. The anthrax lethal factor and its MAPK kinase-specific metalloprotease activity. Mol Aspects Med 2009; 30:431-8.
6. Tournier JN, Rossi Paccani S, Quesnel-Hellmann A, Baldari CT. Anthrax toxins: a weapon to systematically dismantle the host immune defenses. Mol Aspects Med 2009; 30:456-66.
7. Centers for Disease Control and Prevention. Update: adverse events associated with anthrax prophylaxis among postal employees-New Jersey, New York City and the District of Columbia metropolitan area. MMWR 2001; 50:1051-4.
8. Centers for Disease Control and Prevention. Update: use of anthrax vaccine in response to terrorism: supplemental recommendations of the Advisory Committee on Immunization Practices. MMWR 2002; 51:1024-6.
9. BioThrax® (Anthrax Vaccine Adsorbed) Prescribing Information. Emergent BioDefense Operations Lansing Inc., Updated in December 2008.
10. Payne DC, Franzke LH, Stehr-Green PA, Schwartz B, McNeil MM. Development of the Vaccine Analytic Unit's research agenda for investigating potential adverse events associated with anthrax vaccine adsorbed. Pharmacoepidemiol Drug Saf 2007; 16:46-54. (Pubitemid 46164975)
11. Beedham RJ, Turnbull PC, Williamson ED. Passive transfer of protection against Bacillus anthracis infection in a murine model. Vaccine 2001; 19:4409-16. (Pubitemid 32718664)
12. Henderson DW, Peacock S, Belton FC. Observations on the prophylaxis of experimental pulmonary anthrax in the monkey. J Hyg 1956; 54:28-36.
13. Little SF, Leppla SH, Cora E. Production and characterization of monoclonal antibodies to the protective antigen component of Bacillus anthracis toxin. Infect Immun 1988; 56:1807-13.
14. Pitt ML, Little SF, Ivins BE, Fellows P, Barth J, Hewetson J, et al. In vitro correlate of immunity in a rabbit model of inhalational anthrax. Vaccine 2001; 19:4768-73. (Pubitemid 32800762)
15. rd Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology 2003.
16. Beebe LE, Babin M, Barnewall R, Zhong J, Choi G. Post-exposure therapeutic potential of PAmAb in an inhalation model of anthrax in New Zealand White rabbits (NZW) [abstr. 167G]. In: Abstracts of the 2004 American Society for Microbiology Biodefense Research Meeting (Baltimore). Washington, DC: American Society for Microbiology 2004.
17. Mabry R, Rani M, Geiger R, Hubbard GB, Carrion R Jr, Brasky K, et al. Passive protection against anthrax by using a high-affinity antitoxin antibody fragment lacking an Fc region. Infect Immun 2005; 73:8362-8. (Pubitemid 41740327)
18. Mohamed N, Clagett M, Li J, Jones S, Pincus S, D'Alia G, et al. A high-affinity monoclonal antibody to anthrax protective antigen passively protects rabbits before and after aerosolized Bacillus anthracis spore challenge. Infect Immun 2005; 73:795-802. (Pubitemid 40165735)
19. Peterson JW, Comer JE, Noffsinger DM, Wenglikowski A, Walberg KG, Chatuev BM, et al. Human monoclonal anti-protective antigen antibody completely protects rabbits and is synergistic with ciprofloxacin in protecting mice and guinea pigs against inhalation anthrax. Infect Immun 2006; 74:1016-24. (Pubitemid 43185538)
20. Peterson JW, Comer JE, Baze WB, Noffsinger DM, Wenglikowski A, Walberg KG, et al. Human monoclonal antibody AVP-21D9 to protective antigen reduces dissemination of the Bacillus anthracis Ames strain from the lungs in a rabbit model. Infect Immun 2007; 75:3414-24. (Pubitemid 47040942)
21. Sawada-Hirai R, Jiang I, Wang F, Sun SM, Nedellec R, Ruther P, et al. Human anti-anthrax protective antigen neutralizing monoclonal antibodies derived from donors vaccinated with anthrax vaccine adsorbed. J Immune Based Ther Vaccines 2004; 2:5.
22. Vitale L, Blanset D, Lowy I, O'Neill T, Goldstein J, Little SF, et al. Prophylaxis and therapy of inhalational anthrax by a novel monoclonal antibody to protective antigen that mimics vaccine-induced immunity. Infect Immun 2006; 74:5840-7. (Pubitemid 44484571)
23. Wild MA, Kumor K, Nolan MJ, Lockman H, Bowdish KS. A human antibody against anthrax protective antigen protects rabbits from lethal infection with aerosolized spores. Hum Antibodies 2007; 16:99-105. (Pubitemid 351359899)
24. Yusibov V, Rabindran S. Recent progress in the development of plant derived vaccines. Expert Rev Vaccines 2008; 7:1173-83.
25. Mett V, Farrance CE, Green BJ, Yusibov V. Plants as biofactories. Biologicals 2008; 36:354-8. (Pubitemid 50304563)
26. Gomord V, Faye L. Posttranslational modification of therapeutic proteins in plants. Curr Opin Plant Biol 2004; 7:171-81. (Pubitemid 38308053)
27. Jin C, Altmann F, Strasser R, Mach L, Schahs M, Kunert R, et al. A plant-derived human monoclonal antibody induces an anti-carbohydrate immune response in rabbits. Glycobiology 2008; 18:235-41. (Pubitemid 351359690)
28. Bakker H, Rouwendal GJ, Karnoup AS, Florack DE, Stoopen GM, Helsper JP, et al. An antibody produced in tobacco expressing a hybrid beta-1,4- galactosyltransferase is essentially devoid of plant carbohydrate epitopes. Proc Natl Acad Sci USA 2006; 103:7577-82.
29. Tekoah Y, Ko K, Koprowski H, Harvey DJ, Wormald MR, Dwek RA, Rudd PM. Controlled glycosylation of therapeutic antibodies in plants. Arch Biochem Biophys 2004; 426:266-78. (Pubitemid 38680624)
30. Triguero A, Cabrera G, Cremata JA, Yuen CT, Wheeler J, Ramirez NI. Plant-derived mouse IgG monoclonal antibody fused to KDEL endoplasmic reticulum-retention signal is N-glycosylated homogeneously throughout the plant with mostly high-mannose-type N-glycans. Plant Biotechnol J 2005; 3:449-57. (Pubitemid 43923852)
31. Cox KM, Sterling JD, Regan JT, Gasdaska JR, Frantz KK, Peele CG, et al. Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor. Nature Biotechnol 2006; 24:1591-7. (Pubitemid 44967485)
32. Strasser R, Stadlmann J, Schahs M, Stiegler G, Quendler H, Mach L, et al. Generation of glyco-engineered Nicotiana benthamiana for the production of monoclonal antibodies with a homogeneous human-like N-glycan structure. Plant Biotechnol J 2008; 6:392-402. (Pubitemid 351490228)
33. Nuttall J, Ma JK, Frigerio L. A functional antibody lacking N-linked glycans is efficiently folded, assembled and secreted by tobacco mesophyll protoplasts. Plant Biotechnol J 2005; 3:497-504. (Pubitemid 44944504)
34. Rodriguez M, Ramirez NI, Ayala M, Freyre F, Perez L, Triguero A, et al. Transient expression in tobacco leaves of an aglycosylated recombinant antibody against the epidermal growth factor receptor. Biotechnol Bioengin 2005; 89:188-94.
35. Nose M, Wigzell H. Biological significance of carbohydrate chains on monoclonal antibodies. Proc Natl Acad Sci USA 1983; 80:6632-6. (Pubitemid 14240149)
36. Hull AK, Criscuolo CJ, Mett V, Groen H, Steeman W, Westra H, et al. Human-derived, plant-produced monoclonal antibody for the treatment of anthrax. Vaccine 2005; 23:2082-6. (Pubitemid 40341431)
37. Lutcke HA, Chow KC, Mickel FS, Moss KA, Kern HF, Scheele GA. Selection of AUG initiation codons differs in plants and animals. EMBO J 1987; 6:43-8.
38. Vasconcelos D, Barnewall R, Babin M, Hunt R, Estep J, Nielsen C, et al. Pathology of inhalation anthrax in cynomolgus monkeys (Macaca fascicularis). Lab Invest 2003; 83:1201-9. (Pubitemid 37013055)
39. Karginov VA, Robinson TM, Riemenschneider J, Golding B, Kennedy M, Shiloach J, Alibek K. Treatment of anthrax infection with combination of ciprofloxacin and antibodies to protective antigen of Bacillus anthracis. FEMS Immunol Med Microbiol 2004; 40:71-4. (Pubitemid 38083360)
40. Grabenstein JD. Vaccines: countering anthrax: vaccines and immunoglobulins. Clin Infect Dis 2008; 46:129-36.
41. Albrecht MT, Li H, Williamson ED, LeButt CS, Flick-Smith HC, Quinn CP, et al. Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against Bacillus anthracis infection and enhance endogenous immunity to anthrax. Infect Immun 2007; 75:5425-33. (Pubitemid 350033631)
42. Zmuda JF, Zhang L, Sosnovtseva S, Bukreyeva N, Beebe L, Hunt R, Choi GH. Detection of host-derived neutralizing antibodies against anthrax protective antigen (PA) in PAmAb-treated monkeys surviving lethal spore challenge: relationship to secondary exposure immunity, abstr. 65H. Abstr Biodefense Res Meet Am Soc Microbiol 2004. American Society for Microbiology, Washington DC.
43. Subramanian GM, Cronin PW, Poley G, Weinstein A, Stoughton SM, Zhong J, et al. A phase 1 study of PAmAb, a fully human monoclonal antibody against Bacillus anthracis protective antigen, in healthy volunteers. Clin Infect Dis 2005; 41:12-20. (Pubitemid 40863738)
44. Migone TS, Subramanian CM, Zhong J, Healey LM, Corey A, Devalaraja M, et al. Raxibacumab for the treatment of inhalational anthrax. N Engl J Med 2009; 361:135-44.
45. Chichester JA, Musiychuk K, de la Rosa P, Horsey A, Stevenson N, Ugulava N, et al. Immunogenicity of a subunit vaccine against Bacillus anthracis. Vaccine 2007; 25:3111-4. (Pubitemid 46482745)
46. Mett V, Lyons J, Musiychuk K, Chichester JA, Brasil T, Couch R, et al. V. A plant-produced plague vaccine candidate confers protection to monkeys. Vaccine 2007; 25:3014-7. (Pubitemid 46482733)
47. Yusibov V, Mett V, Mett V, Davidson C, Musiychuk K, Gilliam S, et al. Peptide-based candidate vaccine against respiratory syncytial virus. Vaccine 2005; 23:2261-5. (Pubitemid 40341463)
48. Karasev AV, Foulke S, Wellens C, Rich A, Shon KJ, Zwierzynski I, et al. Plant based HIV-1 vaccine candidate: Tat protein produced in spinach. Vaccine 2005;23:1875-80. (Pubitemid 40331862)
49. Pfitzner UM, Goodman HM. Isolation and characterization of cDNA clones encoding pathogenesis-related proteins from tobacco mosaic virus infected tobacco plants. Nucl Acids Res 1987; 15:4449-65.
50. Kapila J, De Rycke R, Van Montagu M, Angenon G. An Agrobacterium-mediated transient gene expression system for intact leaves. Plant Sci 1997; 122:101-9.
51. Lakatos L, Csorba T, Pantaleo V, Chapman EJ, Carrington JC, Liu YP, et al. Small RNA binding is a common strategy to suppress RNA silencing by several viral suppressors. EMBO J 2006; 25:2768-80. (Pubitemid 43980384)
52. Perrier D, Gibaldi M. General derivation of the equation for time to reach a certain fraction of steady state. J Pharm Sci 1982; 71:474-5.
53. Popov SG, Popova TG, Grene E, Klotz F, Cardwell J, Bradburne C, et al. Systemic cytokine response in murine anthrax. Cell Microbiol 2004; 6:225-33. (Pubitemid 38248006)
54. Welkos SL, Keener TJ, Gibbs PH. Differences in susceptibility of inbred mice to Bacillus anthracis. Infect Immun 1986; 51:795-800. (Pubitemid 16162978)
55. Friedlander AM, Welkos SL, Pitt ML, Ezzell JW, Worsham PL, Rose KJ, et al. Postexposure prophylaxis against experimental inhalation anthrax. J Infect Dis 1993; 167:1239-43. (Pubitemid 23115626)